Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal DHEA for Women With Gynecologic and Gastrointestinal Cancer After Radiation
NCT07407647Phase 2Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of dehydroepiandrosterone in Radiation-induced vaginal toxicity (RIVT), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Mar 2026; status: recruiting.
02
Drugs
dehydroepiandrosterone
03
Conditions
Radiation-induced vaginal toxicity (RIVT)
Beyond the preview
Go deeper on NCT07407647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07407647.